Radius Health, Inc. (RDUS) VP Purchases $49,944.02 in Stock

Radius Health, Inc. (NASDAQ:RDUS) VP Brent Hatzis-Schoch bought 1,778 shares of Radius Health stock in a transaction on Friday, November 10th. The stock was acquired at an average cost of $28.09 per share, with a total value of $49,944.02. Following the acquisition, the vice president now owns 2,278 shares in the company, valued at approximately $63,989.02. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of Radius Health, Inc. (NASDAQ:RDUS) traded down $0.16 on Monday, hitting $27.94. The company had a trading volume of 1,116,709 shares, compared to its average volume of 961,724. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79. Radius Health, Inc. has a one year low of $27.16 and a one year high of $55.97.

Radius Health (NASDAQ:RDUS) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The company had revenue of $13.50 million during the quarter, compared to the consensus estimate of $6.90 million. During the same period in the prior year, the firm earned ($1.07) earnings per share. equities research analysts predict that Radius Health, Inc. will post -5.4 EPS for the current fiscal year.

WARNING: This story was first published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.themarketsdaily.com/2017/11/13/radius-health-inc-rdus-vp-purchases-49944-02-in-stock.html.

A number of research firms have commented on RDUS. Cantor Fitzgerald reissued a “buy” rating and issued a $58.00 target price on shares of Radius Health in a report on Friday, November 3rd. Jefferies Group LLC reduced their target price on Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a report on Friday, November 3rd. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $45.00 target price on shares of Radius Health in a report on Friday, October 6th. Zacks Investment Research lowered Radius Health from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Finally, Maxim Group reissued a “positive” rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $51.00.

Several institutional investors and hedge funds have recently modified their holdings of RDUS. Sei Investments Co. grew its holdings in shares of Radius Health by 27.7% in the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 690 shares during the period. Ameritas Investment Partners Inc. lifted its position in Radius Health by 19.9% during the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 541 shares in the last quarter. Advisor Group Inc. lifted its position in Radius Health by 267.2% during the second quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 2,888 shares in the last quarter. Blair William & Co. IL purchased a new position in Radius Health during the second quarter valued at $205,000. Finally, Amalgamated Bank purchased a new position in Radius Health during the second quarter valued at $211,000.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Insider Buying and Selling by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply